The contribution of angiotensin-converting enzyme (ACE) to the metabolism of kinins (bradykinin and des-Arg9-bradykinin) and effect of ACE inhibitors on their in vitro and in vivo metabolism

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-3-0348-7579-0_9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolism of Bradykinin by Peptidases in Health and Disease

  2007cited by this paper
• Comparison of a Vasopeptidase Inhibitor with Neutral Endopeptidase and Angiotensin-Converting Enzyme Inhibitors on Bradykinin Metabolism in the Rat Coronary Bed

  2001cited by this paper
• Anomaly of the des‐Arg9‐bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study

  1999cited by this paper
• Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema.

  1999cited by this paper
• Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes.

  1999cited by this paper
• Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.

  1999cited by this paper
• Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH.

  1999cited by this paper
• Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P.

  1999cited by this paper
• Human gene for physical performance

  1998cited by this paper
• ACE insertion/deletion genotype affects bradykinin metabolism.

  1998cited by this paper
• Plasma bradykinin in angio-oedema.

  1998cited by this paper
• The B1 receptors for kinins.

  1998cited by this paper
• Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin.

  1998cited by this paper
• Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.

  1998cited by this paper
• Metabolism of bradykinin by the rat coronary vascular bed.

  1998cited by this paper
• Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells.

  1997cited by this paper
• Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

  1997cited by this paper
• Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study.

  1997cited by this paper
• The Kinin System

  1997cited by this paper
• The kinin B1 receptor: an inducible G protein coupled receptor.

  1997cited by this paper
• Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation.

  1997cited by this paper
• Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction.

  1996cited by this paper
• Kinin-mediated antihypertensive effect of captopril in deoxycorticosterone acetate-salt hypertension.

  1996cited by this paper
• Bradykinin–evoked sensitization of airway sensory nerves: A mechanism for ACE–inhibitor cough

  1996cited by this paper
• Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells.

  1996cited by this paper
• Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat.

  1996cited by this paper
• Effects of captopril and Icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema.

  1996cited by this paper
• Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.

  1995cited by this paper
• Catalytic properties of the two active sites of angiotensin I-converting enzyme on the cell surface.

  1995cited by this paper
• Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation.

  1995cited by this paper
• Effect of enalaprilat on bradykinin and des‐Arg9‐bradykinin release following reperfusion of the ischaemic rat heart

  1995cited by this paper
• Angiotensin and bradykinin metabolism by peptidases identified in skeletal muscle.

  1995cited by this paper
• Kinin B1 receptors: a review.

  1995cited by this paper
• Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung.

  1995cited by this paper
• Inflammatory peptides at the beginning of hemodialysis in asymptomatic patients treated or not with angiotensin I-converting inhibitors.

  1995cited by this paper
• Kinins and Endothelial Control of Vascular Smooth Muscle

  1995cited by this paper
• Relationships Between Angiotensin I Converting Enzyme Gene Polymorphism, Plasma Levels, and Diabetic Retinal and Renal Complications

  1994cited by this paper
• Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes.

  1994cited by this paper
• Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy.

  1994cited by this paper
• Converting enzyme inhibitors in cardiovascular therapy: current status and future potential.

  1994cited by this paper
• Endothelial protection by converting enzyme inhibitors.

  1994cited by this paper
• A local kallikrein-kinin system is present in rat hearts.

  1994cited by this paper
• Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides.

  1994cited by this paper
• Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects.

  1994cited by this paper
• Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues.

  1994cited by this paper
• Enhancement of cytosolic calcium, prostacyclin and nitric oxide by bradykinin and the ACE inhibitor ramiprilat in porcine brain capillary endothelial cells.

  1994cited by this paper
• Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides.

  1993cited by this paper
• Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells.

  1993cited by this paper
• Metabolism of bradykinin by peptidases in the lung.

  1993cited by this paper
• Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation.

  1993cited by this paper
• Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure.

  1993cited by this paper
• Measurement of angiotensin I converting enzyme inhibition in the heart.

  1993cited by this paper
• Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors.

  1993cited by this paper
• Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor

  1993cited by this paper
• Ramiprilat increases bradykinin outflow from isolated hearts of rat

  1993cited by this paper
• The kallikrein--kinin system in blood vessels.

  1992cited by this paper
• Production of cyclic GMP via activation of B1 and B2 kinin receptors in cultured bovine aortic endothelial cells.

  1992cited by this paper
• Bioregulation of kinins: kallikreins, kininogens, and kininases.

  1992cited by this paper
• Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction

  1992cited by this paper
• Bradykinin Degrading Activity in Cultured Human Endothelial Cells

  1992cited by this paper
• Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides.

  1992cited by this paper
• Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System

  1991cited by this paper
• Localization of angiotensin converting enzyme in rat heart.

  1991cited by this paper
• Metabolism of bradykinin analogs by angiotensin I converting enzyme and carboxypeptidase N.

  1991cited by this paper
• Local Inhibition of Bradykinin Degradation in Ischemic Hearts

  1990cited by this paper
• An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

  1990cited by this paper
• Contributions of various rat plasma peptidases to kinin hydrolysis.

  1989cited by this paper
• Epicardial application of bradykinin elicits pressor effects and tachycardia in guinea pigs. Possible mechanisms.

  1987cited by this paper
• Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo.

  1987cited by this paper
• Studies of the digestion of bradykin, lys-bradykinin, and des-Arg9-bradykinin by angiotensin converting enzyme

  1986cited by this paper
• Structure and functions of human angiotensin I converting enzyme (kininase II).

  1985cited by this paper
• Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension--before and after treatment with enalapril (MK 421).

  1983cited by this paper
• Activation of angiotensin converting enzyme by monovalent anions.

  1983cited by this paper
• Substrate specificity and kinetic characteristics of angiotensin converting enzyme.

  1983cited by this paper
• The degradation of bradykinin (BK) and of des-Arg9-BK in plasma.

  1981cited by this paper
• 2 Inhibitiors of Angiotensin-Converting Enzyme

  1980cited by this paper
• Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. Importance of the COOH-terminal dipeptide sequence.

  1980cited by this paper
• Hydrolysis of Bradykinin by Angiotensin‐Converting Enzyme

  1974cited by this paper
• Urinary Kallikrein Excretion in Hypertensive Man: Relationships to Sodium intake and Sodium‐Retaining Steroids

  1974cited by this paper
• Hydrolysis of bradykinin and its higher homologues by angiotensin-converting enzyme.

  1974cited by this paper
• Conversion of Angiotensin I to Angiotensin II by Cell-free Extracts of Dog Lung

  1968cited by this paper
• Fate of Angiotensin I in the Circulation

  1968cited by this paper
• The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat.

  1967cited by this paper
• A Bradykinin-Potentiating Factor (BPF) present in the Venom of Bothrops jararaca.

  1965cited by this paper

• Transcriptomic impacts and potential routes of detoxification in a lampricide-tolerant teleost exposed to TFM and niclosamide

  2023cites this paper
• Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents

  2017cites this paper
• Temoporfin (Foscan®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer †,‡

  2011cites this paper
• Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics.

  2002cites this paper
• Bradykinin, an Important Mediator of the Cardiovascular Effects of Metallopeptidase Inhibitors: Experimental and Clinical Evidences

  2001cites this paper
• Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.

  2000cites this paper
• The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins.

  2000cites this paper